Navigation Links
Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
Date:6/19/2008

SOUTH SAN FRANCISCO, Calif., June 19 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will provide a corporate update at the upcoming Jefferies 2nd Annual Healthcare Conference at 2:00 p.m. Eastern Time on June 26, 2008 at the Mandarin Oriental in New York, NY.

Interested parties may access a webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin (formerly SNS-595), in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
3. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
4. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
7. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
8. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Sept. 16, 2014  The Council for Entrepreneurial ... organization in the country, today released a mid-year ... It showed that in the ... startups in the technology, life science, ... investment from a variety of sources. Significant investment in ...
(Date:9/16/2014)... Arizona (PRWEB) September 16, 2014 ... develops safe and effective products to treat patients ... use of a proprietary SPACEā„¢ Technology Platform announced ... and President will present at the White Hat ... at the Hyatt Regency Phoenix. In addition, ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... , June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for ... for treating cell proliferative disorders by administering modified vaccinia virus to ... , , ...
... June 17 ChemoCentryx, Inc., today announced that ... drug candidate CCX354 at the Annual European Congress of ... drug candidate designed to specifically target the CCR1 chemokine ... (RA).  Data demonstrating that CCX354 was safe and well ...
... Researchers at Rensselaer Polytechnic Institute have developed a ... that measure only billionths of a meter thick. ... works on nearly any surface including silicon wafers, ... manufacturing. Sang-Kee Eah, assistant professor in the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 3ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 4Researchers develop ultra-simple method for creating nanoscale gold coatings 2
(Date:9/17/2014)... their environmental impact recently scored a major win. In ... the bags, and Governor Jerry Brown is expected to ... yielding without a fight, according to an article in ... of the American Chemical Society. , Alexander Tullo, a ... logged its first small victory in 1990 when Nantucket ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... mountain meadows in the Pacific Northwest are declining rapidly due ... growing seasons and other factors allow trees to invade these ... wildflowers. The process appears to have been going on ... Jefferson Park, a subalpine meadow complex in the central Oregon ...
... Planck Institute for Chemical Energy Conversion (MPI CEC) and ... on a hydrogen-producing enzyme that the environment of the ... enzyme. Thus, it can very efficiently produce hydrogen, which ... research team describes their results in the journal " ...
... Calif.During the early developmental stages of vertebratesanimals that ... undergo extensive rearrangements, and some cells migrate over ... novel roles as differentiated cell types. Understanding how ... an embryo is an important and complex goal ...
Cached Biology News:Mountain meadows dwindling in the Pacific Northwest 2Temporary storage for electrons: Natural method of producing hydrogen 2Developmental bait and switch 2Developmental bait and switch 3
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
SHEEP ANTI HUMAN CATHEPSIN G...
Request Info...
RABBIT ANTI TRANSFERRIN RECEPTOR...
Biology Products: